
CNS Pharmaceuticals fell 55.6% from $6.51 to $2.89, behind the S&P 500's +13.3%. Its worst day was Nov 13 (−21.3%), and its low came Apr 9 at $2.13.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-5.76 beat the $-6.63 estimate on $0.00 revenue.
0.0% · S&P 500 −0.9%
EPS of $-10.15 missed the $-5.37 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−5.4% · S&P 500 +0.8%
CNS Pharmaceuticals closed at its lowest level of the year, 67.3% below where the year started.
−2.3% · S&P 500 +0.6%
CNS Pharmaceuticals closed at its highest level of the year, 20.4% above where the year started.
+233.6%, the year's best day, on 84M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $-7.30 missed the $-5.37 estimate on $0.00 revenue.
−9.2% · S&P 500 +0.8%
EPS of $-0.38 missed the $-0.24 estimate on $0.00 revenue.
−5.6% · S&P 500 +0.3%
Where it ended: a close of $2.89 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 16, 2026 (EPS est. $-0.27).
Nothing in the past 12 months.
All CNSP analyst actionsNothing in the past 12 months.
All CNSP dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CNSP and SPY from Benzinga historical bars. Not investment advice.